Covid 19 ietekme uz Noofen un Adaptol lietojumu

Abstract

Medikamenti Noofen un Adaptol pieejami Latvijā kā recepšu zāles dažādās devās un formās. Tie mazina trauksmi un nemieru. Darba mērķis ir noskaidrot kā Covid-19 pandēmija ir ietekmējusi medikamentu Noofen un Adaptol lietošanu. Pētījums ļauj novērtēt, vai pandēmijas ietekmē cilvēkiem biežāk tika nozīmēti medikamenti Noofen un Adaptol trauksmes mazināšanai un vai šo medikamentu lietošana sniedza vēlamo rezultātu. Iegūtie dati liecina, ka Covid-19 pandēmijas laikā ārsti bieži nozīmēja medikamentus Noofen un/vai Adaptol, visbiežāk tie tika nozīmēti pirmreizēji un lietoti monoterapijā 1-2 mēnešus. Gan ārsti, gan pacienti norādīja, ka medikamenti Noofen un/vai Adaptol sniedz vēlamos rezultātus.

Noofen and Adaptol are available in Latvia as prescription medicines in different doses and forms. They are used to reduce anxiety. The aim of the work is to find out how Covid-19 pandemic has affected the use of the drugs Noofen and Adaptol. The study allows to discover whether people were more often prescribed the anti-anxiety drugs Noofen and Adaptol due to the pandemic, and whether the use of these drugs had the desired effect. It was found, that during the Covid-19 pandemic, physicians often prescribed the drugs Noofen and/or Adaptol, most often they were prescribed for the first time and used in monotherapy for 1-2 months. Both physicians and patients indicated that the drugs Noofen and/or Adaptol provide the desired results.